Neogen Corporation (NEOG) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
53/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseNEOG / S&P -3.23% / 15.20% |
LoseNEOG / S&P -2.72% / 15.00% |
LoseNEOG / S&P -99.20% / 50.40% |
| 2026-Q11/3 |
WinNEOG / S&P 32.90% / -4.33% |
LoseNEOG / S&P -3.91% / 11.30% |
LoseNEOG / S&P 25.56% / 27.70% |
| 2025-Q42/3 |
WinNEOG / S&P 22.42% / 2.65% |
LoseNEOG / S&P -3.66% / 9.00% |
WinNEOG / S&P 26.48% / 13.40% |
| 2025-Q32/3 |
WinNEOG / S&P 19.46% / 8.12% |
LoseNEOG / S&P -2.77% / 4.61% |
WinNEOG / S&P 4263.64% / 13.45% |
| 2025-Q21/3 |
LoseNEOG / S&P -44.87% / 10.94% |
LoseNEOG / S&P -3.19% / 4.83% |
WinNEOG / S&P 12475.00% / 10.63% |
| 2025-Q10/3 |
LoseNEOG / S&P -28.58% / -4.27% |
LoseNEOG / S&P -2.50% / 4.98% |
LoseNEOG / S&P -11250.00% / 10.57% |
| 2024-Q40/3 |
LoseNEOG / S&P -27.78% / 2.41% |
LoseNEOG / S&P -0.53% / 5.25% |
LoseNEOG / S&P -3228.57% / 6.15% |
| 2024-Q32/3 |
WinNEOG / S&P 7.55% / 5.89% |
LoseNEOG / S&P -0.75% / 5.89% |
WinNEOG / S&P 10.00% / 6.11% |
| 2024-Q21/3 |
LoseNEOG / S&P -0.95% / 4.28% |
WinNEOG / S&P 12.37% / 5.38% |
LoseNEOG / S&P -33.33% / 5.12% |
| 2024-Q11/3 |
LoseNEOG / S&P -21.53% / 10.56% |
WinNEOG / S&P 28.93% / 5.71% |
LoseNEOG / S&P -50.00% / 5.59% |
| 2023-Q42/3 |
LoseNEOG / S&P 8.47% / 11.69% |
WinNEOG / S&P 45.66% / 6.81% |
WinNEOG / S&P 40.00% / 7.78% |
| 2023-Q31/3 |
LoseNEOG / S&P -14.76% / -3.27% |
WinNEOG / S&P 73.02% / 7.52% |
LoseNEOG / S&P -129.41% / -5.03% |
| 2023-Q22/3 |
WinNEOG / S&P 17.44% / 8.74% |
WinNEOG / S&P 56.01% / 9.50% |
LoseNEOG / S&P -113.33% / -8.57% |
| 2023-Q12/3 |
WinNEOG / S&P 21.60% / 7.50% |
WinNEOG / S&P 40.09% / 10.77% |
LoseNEOG / S&P -91.30% / -15.69% |
| 2022-Q42/3 |
WinNEOG / S&P 9.02% / 7.56% |
WinNEOG / S&P 25.40% / 11.88% |
LoseNEOG / S&P -90.57% / -17.99% |
| 2022-Q30/3 |
LoseNEOG / S&P -42.01% / -4.88% |
LoseNEOG / S&P 8.98% / 13.47% |
LoseNEOG / S&P -41.38% / -1.41% |
| 2022-Q20/3 |
LoseNEOG / S&P -21.89% / -16.10% |
LoseNEOG / S&P 12.53% / 13.71% |
LoseNEOG / S&P -21.05% / 11.04% |
| 2022-Q11/3 |
LoseNEOG / S&P -32.09% / -4.60% |
LoseNEOG / S&P 14.30% / 15.97% |
WinNEOG / S&P 187.50% / 42.23% |
| 2021-Q41/3 |
LoseNEOG / S&P 4.56% / 11.03% |
WinNEOG / S&P 16.08% / 15.00% |
LoseNEOG / S&P 96.30% / 96.40% |
| 2021-Q31/3 |
LoseNEOG / S&P -5.67% / 0.58% |
WinNEOG / S&P 14.40% / 10.77% |
LoseNEOG / S&P 34.88% / 69.42% |
| 2021-Q21/3 |
LoseNEOG / S&P 3.59% / 8.55% |
WinNEOG / S&P 12.03% / 6.58% |
LoseNEOG / S&P 1.79% / 51.81% |
| 2021-Q12/3 |
WinNEOG / S&P 12.09% / 6.17% |
WinNEOG / S&P 7.46% / -1.06% |
LoseNEOG / S&P -70.37% / 7.39% |
| 2020-Q41/3 |
LoseNEOG / S&P 1.34% / 12.15% |
WinNEOG / S&P 3.98% / -3.72% |
LoseNEOG / S&P -51.79% / -33.42% |
| 2020-Q32/3 |
LoseNEOG / S&P 0.84% / 8.93% |
WinNEOG / S&P 2.42% / -2.04% |
WinNEOG / S&P -23.21% / -27.10% |
| 2020-Q22/3 |
LoseNEOG / S&P 15.84% / 20.54% |
WinNEOG / S&P 0.96% / -0.46% |
WinNEOG / S&P -1.75% / -27.11% |
| 2020-Q11/3 |
WinNEOG / S&P 2.65% / -19.60% |
LoseNEOG / S&P 1.53% / 3.47% |
LoseNEOG / S&P -54.24% / -14.75% |
| 2019-Q40/3 |
LoseNEOG / S&P -4.18% / 9.07% |
LoseNEOG / S&P 1.69% / 5.36% |
LoseNEOG / S&P -55.20% / 2.99% |
| 2019-Q31/3 |
WinNEOG / S&P 9.66% / 1.70% |
LoseNEOG / S&P 3.13% / 5.02% |
LoseNEOG / S&P -55.91% / 0.21% |
| 2019-Q21/3 |
WinNEOG / S&P 8.22% / 4.30% |
LoseNEOG / S&P 4.09% / 6.64% |
LoseNEOG / S&P -52.89% / 8.65% |
| 2019-Q10/3 |
LoseNEOG / S&P 0.68% / 13.65% |
LoseNEOG / S&P 7.06% / 8.12% |
LoseNEOG / S&P 4.42% / 14.29% |
| 2018-Q41/3 |
LoseNEOG / S&P -20.31% / -13.52% |
LoseNEOG / S&P 8.16% / 9.05% |
WinNEOG / S&P 23.76% / 18.23% |
| 2018-Q31/3 |
LoseNEOG / S&P -10.80% / 7.71% |
LoseNEOG / S&P 9.35% / 10.21% |
WinNEOG / S&P 41.11% / 19.06% |
| 2018-Q23/3 |
WinNEOG / S&P 19.70% / 3.43% |
WinNEOG / S&P 11.07% / 9.03% |
WinNEOG / S&P 30.11% / 14.46% |
| 2018-Q13/3 |
WinNEOG / S&P 8.62% / -0.76% |
WinNEOG / S&P 9.22% / 7.68% |
WinNEOG / S&P 63.77% / 12.46% |
| 2017-Q42/3 |
LoseNEOG / S&P 6.13% / 6.64% |
WinNEOG / S&P 11.04% / 7.03% |
WinNEOG / S&P 42.25% / 13.82% |
| 2017-Q33/3 |
WinNEOG / S&P 12.08% / 4.48% |
WinNEOG / S&P 11.75% / 5.68% |
WinNEOG / S&P 23.29% / 17.57% |
| 2017-Q23/3 |
WinNEOG / S&P 5.43% / 3.09% |
WinNEOG / S&P 11.52% / 4.83% |
WinNEOG / S&P 29.17% / 17.74% |
| 2017-Q11/3 |
LoseNEOG / S&P -0.68% / 6.07% |
WinNEOG / S&P 13.89% / 3.67% |
LoseNEOG / S&P -28.13% / 13.32% |
| 2016-Q42/3 |
WinNEOG / S&P 17.98% / 3.82% |
WinNEOG / S&P 13.16% / 2.09% |
LoseNEOG / S&P -24.47% / 7.05% |
| 2016-Q31/3 |
LoseNEOG / S&P -0.55% / 3.85% |
WinNEOG / S&P 13.68% / 0.20% |
LoseNEOG / S&P -19.78% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NEOG total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 104.17% | 20.78% |
| Annualized return | 104.17% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NEOG total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -73.41% | 83.14% |
| Annualized return | -23.27% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | NEOG total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -47.41% | 319.30% |
| Annualized return | -6.23% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |